NCT06818474View on ClinicalTrials.gov

Lanadelumab in Long-term Prophylaxis of Acquired Angioedema

PHASE4RecruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

September 1, 2027

Study Completion Date

December 1, 2027

Conditions
Angioedema
Interventions
BIOLOGICAL

Lanadelumab 300 mg

no other intervention

Trial Locations (1)

45236

RECRUITING

Bernstein Clinical Research Center, LLC, Cincinnati

Sponsors
All Listed Sponsors
lead

Bernstein Clinical Research Center

OTHER